Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
This research aims to provide continued access to HIV treatment for participants who completed previous ViiV Healthcare-sponsored or collaborative parent studies and are still benefiting from the study treatment but lack local access. The study focuses on collecting ongoing safety data while offering this extended treatment opportunity. Participants must have completed the treatment period in the parent study and continue to experience clinical benefits. Participants receive oral tablets of Fostemsavir and Dolutegravir DTG Lamivudine 3TC, with dosages depending on their weight. This open-label study includes a single group of participants transitioning from their parent studies to continued access. The study spans several years, allowing long-term treatment and monitoring. During the study, participants comply with scheduled visits, treatment plans, and study procedures. Researchers monitor safety by recording discontinuations, serious adverse events, and adverse events of special interest throughout the study period. Participation continues until withdrawal or study end, with ongoing assessment of treatment tolerability and safety.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of regimens containing quabodepistat for treating rifampicin-resistant or multidrug-resistant pulmonary tuberculosis in this Phase 3, randomized, open-label, multicenter trial. Participants are divided into two groups based on fluoroquinolone susceptibility and randomized to receive either experimental or control treatment regimens. The study aims to provide shorter, well-tolerated treatment options for drug-resistant tuberculosis. Participants with fluoroquinolone-susceptible tuberculosis are randomized to a 4-month experimental regimen including bedaquiline, pretomanid, quabodepistat, and moxifloxacin or a 6-month control regimen with bedaquiline, pretomanid, linezolid, and moxifloxacin. Those with fluoroquinolone-resistant tuberculosis receive either a 6-month experimental regimen of bedaquiline, pretomanid, and quabodepistat or a 6-month control regimen of bedaquiline, pretomanid, and linezolid. Doses vary by drug and regimen, with some adjustments permitted for toxicity. Participants are followed for approximately 16 months after randomization, with evaluations including sputum samples, chest X-rays, and monitoring of adverse events. The main outcome measured is the proportion of participants with unfavorable outcomes at 12 months post-randomization. Other assessments include treatment-emergent adverse events, sputum culture conversion, relapse, and reinfection. Follow-up visits may extend to week 72 for ongoing safety or relapse monitoring.
Actively Recruiting
Researchers are studying adults aged 18 to 45 years with newly diagnosed, bacteriologically confirmed drug-sensitive pulmonary tuberculosis. This trial evaluates whether adding omega-3 long-chain polyunsaturated fatty acids n-3 LCPUFA to standard tuberculosis treatment can shorten the time it takes for sputum cultures to become positive, reduce inflammation, and improve treatment outcomes compared to a placebo. The study is a randomized controlled trial designed to assess early bactericidal activity, early inflammatory response, and safety of the supplementation. Participants are randomly assigned to receive either approximately 2 grams of omega-3 fatty acids EPA and DHA daily through three 1-gram fish oil capsules or a matching placebo of high linoleic sunflower oil capsules. This supplementation is given alongside the intensive phase of tuberculosis treatment for eight weeks. The study includes a parallel comparison between the omega-3 group and the placebo group. During the study, participants attend a baseline clinical visit followed by mostly weekly follow-up visits for two months, then monthly visits for four months during the continuous phase of tuberculosis treatment. They provide blood, sputum, and urine samples for biomarker and metabolomic analyses and undergo assessments of iron status, body composition, and muscle strength. Researchers measure sputum culture time to positivity at multiple points and monitor inflammatory markers, safety, and clinical outcomes throughout the trial.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of the MTBVAC vaccine in adolescents and adults aged 12 to 55 years, both living with and without HIV in South Africa. This Phase 2a clinical trial aims to compare MTBVAC with the BCG vaccine in participants grouped based on their HIV status, CD4 T cell count, and interferon-gamma release assay IGRA status. The study is conducted by the HIV Vaccine Trials Network and involves randomized assignment without a placebo group. Participants will receive a single intradermal injection of either MTBVAC or BCG vaccine, each at a volume of 0.1 mL, administered in the upper arm at the start of the study. The study is divided into two parts and three cohorts, with enrollment proceeding sequentially based on safety criteria. Follow-up will continue for 48 weeks after vaccination to monitor safety and immune responses. During the study, participants will undergo various assessments including monitoring for adverse events up to 48 weeks, measurement of specific immune cell responses at baseline and multiple time points, gene expression profiling, and antibody levels. Researchers will also evaluate the acceptability of the vaccines. Safety monitoring includes tracking serious and solicited adverse events, with a focus on immune markers such as CD4 and CD8 T cells expressing certain cytokines. Participants will be asked to attend scheduled visits for these assessments throughout the study period.
Actively Recruiting
People living with HIV who have recently been discharged from the hospital face a higher risk of poor health outcomes, including death. This study evaluates whether providing structured home-based care, with or without nutritional support, can help reduce the risk of death within six months after discharge and improve long-term health. The trial is a randomized clinical study that also looks at how practical and acceptable these home care approaches are in real-world settings. Participants are randomly assigned to one of three groups standard post-discharge care, home-based care with medical assessments and psychosocial support, or home-based care combined with food parcels for nutritional support. The home visits start one week after discharge and occur every two weeks, totaling 4 to 6 visits. Those in the nutritional support group receive three food parcel deliveries at weeks 1, 5, and 9. The care during home visits includes medication adherence support, clinical assessments, lab specimen collection, and counseling. During the study, participants are monitored for mortality up to 12 months after discharge, rehospitalization, viral load suppression, and weight changes. Researchers also assess how well the interventions are delivered, their acceptance by patients and families, and the economic impact of illness on households. The study spans several years, with enrollment starting in 2025 and follow-up continuing through 2029, aiming to provide evidence to improve care for people living with HIV after hospital discharge.
Actively Recruiting
Healthy Volunteer
This research aims to better understand how immune responses in the blood and mucosal areas protect young children aged 2 to 5 years from influenza infection and illness. The study will compare immune responses in children who get influenza to those who do not, focusing on identifying immune markers that may predict protection against infection, illness, and virus shedding. The study is observational and takes place during the 2026 influenza season in South Africa. Participants will be followed from April through October 2026. Nasal swabs will be collected three times per week to test for influenza and other respiratory viruses, with one swab collected by study nurses during a household visit and two collected by caregivers. Blood samples will be taken before and after the influenza season and at two additional points during the study. Monthly samples from the nose and mouth will also be collected to measure immune responses, including antibodies, cytokines, and specific immune cells. Throughout the study, nurses will collect symptom and temperature data at weekly visits, while caregivers will record symptoms daily using an electronic diary. Researchers will analyze immune markers from blood and mucosal samples to find correlations with protection from influenza infection and illness, viral load, and duration of virus shedding. The study will also monitor immune responses over time and evaluate the impact of co-infections. Participation involves regular sample collection and symptom monitoring over six months.
Actively Recruiting
Researchers are evaluating whether taking azithromycin as a preventive treatment can reduce the risk of death in adults with advanced HIV disease. This is a Phase 3, double-blind, placebo-controlled trial involving multiple centers. The study aims to understand if azithromycin prophylaxis can lower mortality compared to a placebo in this vulnerable population. Participants will be randomly assigned to receive either an oral azithromycin tablet or a matching placebo tablet once daily for 28 days. After this treatment period, they will be followed for 24 weeks to measure the main outcome of all-cause mortality. The total study participation will last 48 weeks to monitor both short-term and longer-term effects. During the study, participants will undergo assessments to track survival and hospitalizations at 12 and 24 weeks after starting the treatment. Researchers will closely monitor health outcomes and any hospital stays to evaluate the impact of azithromycin prophylaxis. Safety and adherence will be followed throughout the trial to ensure accurate measurement of results.
Actively Recruiting
The RIC-AFRICA trial is a multi-center, sham-controlled, randomized controlled trial involving 1400 patients who have experienced ST-segment elevation myocardial infarction STEMI within 24 hours of symptom onset. The study aims to find out if Remote Ischaemic Conditioning RIC can reduce death rates and early heart failure after a heart attack in patients mainly treated with clot-busting therapy. It also includes an observational group of patients presenting between 24 and 72 hours after the heart attack to study similar outcomes without treatment intervention. Participants are randomly assigned to either the RIC group or a sham control group. Those in the RIC group will receive four cycles of blood pressure cuff inflation to 20 mmHg above their systolic blood pressure for 5 minutes, followed by 5 minutes of deflation, repeated four times, and this protocol will be repeated daily for two more days. The sham group will undergo the same cycle with low-pressure inflation to 20 mmHg. The observational group, who present later, will not receive intervention but will be followed with the same outcome measures. Throughout the study, participants will be monitored for all-cause death and new onset heart failure within 30 days after the heart attack. Assessments will include clinical evaluations, ECG, biomarkers, and echocardiography to confirm STEMI and heart function. The study will also track major adverse cardiac and cerebrovascular events at 30 days. The total participation duration varies based on the group, with interventions over three days for the randomized groups and observation for up to 72 hours for the non-randomized group.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two sorfequiline-based treatment regimens combined with pretomanid and linezolid for adults aged 18 to 65 with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis. This phase 2, randomized, multi-center, partially blinded trial involves about 100 participants in South Africa and Tanzania and aims to assess treatment safety and bacterial culture conversion times. Participants are randomly assigned to one of two oral treatment groups one receives a loading dose regimen of sorfequiline 200 mg daily for 4 weeks followed by 100 mg daily for 13 weeks, and the other receives sorfequiline 100 mg daily for 17 weeks. Both groups also take pretomanid 200 mg and linezolid 600 mg daily, with the treatment administered once daily with food. The trial includes a screening period up to 11 days before treatment, a 17-week treatment period, and a 52-week follow-up after treatment ends. During the study, participants will undergo safety monitoring including assessments of adverse events, ECGs, vital signs, lab tests, vision checks, and peripheral neuropathy evaluations. Researchers will also measure treatment efficacy by monitoring time to stable sputum culture conversion and treatment outcomes at 26 and 52 weeks post-treatment. Pharmacokinetics and quality of life are additionally assessed throughout the study duration.